TYME News and Press, Tyme Technologies Inc. From 08/26/20

TYME-19 is an oral synthetic bile acid that has demonstrated broad spectrum antiviral activity as well as efficacy against COVID-19 in preclinical studies Initiating proof-of-concept RESPOnD trial to investigate TYME-19 for safety and efficacy in recently diagnosed, symptomatic COVID-1...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will present at the 2020 Cross-Border Healthcare Webinar Series on Wednesday, August 26, 2020. The Company will present its corpo...

Tyme Technologies, Inc. (NASDAQ: TYME, an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs ™ ), announced the appointment of John Rothman Ph.D. as Executive Vice President, Product Development. “Dr. Rothman is an accomplished pharmaceutica...

Principal Investigator of the HopES Sarcoma Study Recommended Continuation of the Trial Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today a positive outcome of an interim futility ...

DBV Technologies DBVT  -34%  on FDA rejection of Viaskin Peanut application. More news on: Grindrod Shipping Holdings Ltd., Moxian, Inc., Marathon Patent Group, Inc., Stocks on the move, , Read more ...

Tyme Technologies  (NASDAQ: TYME )   +28%  premarket, on the heels of U.S. Orphan Drug tag for SM-88 (racemetyrosine) for pancreatic cancer. More news on: Tyme Technologies, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Highway Holdings (NASDAQ: HIHO ) +102% . More news on: Highway Holdings Limited, ADT Inc., CymaBay Therapeutics, Inc., Stocks on the move, , Read more ...

SM-88 has demonstrated encouraging tumor responses in 15 different cancers across four separate studies with minimal serious grade 3 or higher adverse events TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer. ...

Natuzzi (NYSE: NTZ ) +131%  on renewing its securitization facility. More news on: Natuzzi S.p.A., Miragen Therapeutics, Theratechnologies Inc., Stocks on the move, Read more ...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will participate at the Canaccord 40 th Annual Growth Conference on Thursday, August 13, 2020. The Company will present its ...